問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳正哲

Recruiting

List

45Cases

2024-12-30 - 2031-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2017-01-01 - 2021-12-31

Phase III

A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Olaparib

Participate Sites
9Sites

Recruiting5Sites

Terminated4Sites

2021-06-01 - 2022-05-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2020-04-01 - 2024-01-10

Phase III

A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer

  • Condition/Disease

    Metastatic Castration-resistant Prostate Cancer

  • Test Drug

    OPDIVO (nivolumab) Injection 10mg/mL

Participate Sites
6Sites

Recruiting6Sites

2014-07-15 - 2021-03-30

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer

  • Condition/Disease

    NA

  • Test Drug

    ARN-509; softgel capsule

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB